Univariate analyses of patients who underwent unrelated donor transplantation for AML, by disease status prior to transplantation and cytogenetics risk group
| Outcome . | Favorable . | Intermediate . | Unfavorable . | P* . |
|---|---|---|---|---|
| First complete remission, n | 13 | 164 | 84 | |
| Treatment-related mortality, %, (95% CI) | ||||
| At 100 d | 46 (21-72) | 32 (25-39) | 29 (19-39) | .48 |
| At 3 y | 63 (36-87) | 50 (42-57) | 47 (36-58) | .55 |
| At 5 y | 63 (36-87) | 53 (45-62) | 47 (36-58) | .46 |
| Relapse, no. %, (95% CI) | ||||
| At 3 y | 8 (0-28) | 17 (11-23) | 26 (17-36) | .10 |
| At 5 y | 8 (0-28) | 17 (11-23) | 26 (17-36) | .10 |
| Disease-free survival, no. %, (95% CI) | ||||
| At 3 y | 29 (8-56) | 33 (26-41) | 29 (19-39) | .73 |
| At 5 y | 29 (8-56) | 30 (22-38) | 27 (19-39) | .92 |
| Overall survival, %, (95% CI) | ||||
| At 3 y | 29 (8-56) | 35 (27-42) | 32 (22-42) | .85 |
| At 5 y | 29 (8-56) | 30 (22-38) | 30 (20-41) | .99 |
| Second complete remission, n | 97 | 165 | 37 | |
| Treatment-related mortality, %, (95% CI) | ||||
| At 100 d | 27 (19-36) | 22 (16-28) | 16 (6-30) | .34 |
| At 3 y | 46 (40-52) | 44 (36-51) | 30 (16-45) | .13 |
| At 5 y | 46 (36-56) | 46 (39-54) | 30 (16-45) | .13 |
| Relapse, %, (95% CI) | ||||
| At 3 y | 12 (6-19) | 17 (12-24) | 32 (19-48) | .038 |
| At 5 y | 12 (6-19) | 18 (13-25) | 32 (19-48) | .033 |
| Disease-free survival, %, (95% CI) | ||||
| At 3 y | 42 (33-52) | 39 (32-47) | 38 (23-54) | .83 |
| At 5 y | 42 (33-52) | 35 (28-43) | 38 (23-54) | .56 |
| Overall survival, no. %, (95% CI) | ||||
| At 3 y | 45 (35-55) | 42 (35-50) | 41 (25-57) | .86 |
| At 5 y | 45 (35-55) | 37 (30-45) | 36 (21-53) | .45 |
| Outcome . | Favorable . | Intermediate . | Unfavorable . | P* . |
|---|---|---|---|---|
| First complete remission, n | 13 | 164 | 84 | |
| Treatment-related mortality, %, (95% CI) | ||||
| At 100 d | 46 (21-72) | 32 (25-39) | 29 (19-39) | .48 |
| At 3 y | 63 (36-87) | 50 (42-57) | 47 (36-58) | .55 |
| At 5 y | 63 (36-87) | 53 (45-62) | 47 (36-58) | .46 |
| Relapse, no. %, (95% CI) | ||||
| At 3 y | 8 (0-28) | 17 (11-23) | 26 (17-36) | .10 |
| At 5 y | 8 (0-28) | 17 (11-23) | 26 (17-36) | .10 |
| Disease-free survival, no. %, (95% CI) | ||||
| At 3 y | 29 (8-56) | 33 (26-41) | 29 (19-39) | .73 |
| At 5 y | 29 (8-56) | 30 (22-38) | 27 (19-39) | .92 |
| Overall survival, %, (95% CI) | ||||
| At 3 y | 29 (8-56) | 35 (27-42) | 32 (22-42) | .85 |
| At 5 y | 29 (8-56) | 30 (22-38) | 30 (20-41) | .99 |
| Second complete remission, n | 97 | 165 | 37 | |
| Treatment-related mortality, %, (95% CI) | ||||
| At 100 d | 27 (19-36) | 22 (16-28) | 16 (6-30) | .34 |
| At 3 y | 46 (40-52) | 44 (36-51) | 30 (16-45) | .13 |
| At 5 y | 46 (36-56) | 46 (39-54) | 30 (16-45) | .13 |
| Relapse, %, (95% CI) | ||||
| At 3 y | 12 (6-19) | 17 (12-24) | 32 (19-48) | .038 |
| At 5 y | 12 (6-19) | 18 (13-25) | 32 (19-48) | .033 |
| Disease-free survival, %, (95% CI) | ||||
| At 3 y | 42 (33-52) | 39 (32-47) | 38 (23-54) | .83 |
| At 5 y | 42 (33-52) | 35 (28-43) | 38 (23-54) | .56 |
| Overall survival, no. %, (95% CI) | ||||
| At 3 y | 45 (35-55) | 42 (35-50) | 41 (25-57) | .86 |
| At 5 y | 45 (35-55) | 37 (30-45) | 36 (21-53) | .45 |
Pointwise P value.